What should be monitored when using Dilantin for seizure management?

When using Dilantin (phenytoin) for seizure management, it is essential to monitor the potential for crystallization, particularly when it is administered in combination with dextrose (D5W). Dilantin is known to be sensitive to certain conditions, and when mixed with dextrose solutions, it can precipitate or crystallize. This is crucial because crystallization can lead to complications in administration, such as blockage of intravenous lines, and can affect the effective delivery of the medication.

Therefore, ensuring that Dilantin does not crystallize when given with D5 ensures the medication remains effective and safe for the patient. Monitoring for this aspect during administration helps healthcare professionals maintain the integrity of the treatment protocol for seizure management.